Scalable production in single-use bioreactors
On demand

Scalable production in single-use bioreactors

Wednesday 08:30 IST / 11:00 +08 / 12:00 KST / 12:00 JST / 11:00 AWST / 16:00 NZDT
Scalable production in single-use bioreactors

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Production of high-titer AAV at clinical scales remains a challenge for the gene therapy industry. Developers need to understand how to optimize, scale, and qualify their manufacturing process for AAV production under the tightest of time lines.

Due to high demand in the gene therapy space, effective solutions to address these challenges must be developed and implemented.

This webinar will discuss how to meet the needs of this fast-moving industry and answer key questions on AAV production, purification, and processes.

As a webinar attendee, you will learn about:

  • Enabling scalable, high-titer AAV production in single-use bioreactors
  • How to optimize recovery and purity in downstream processing
  • Robust and efficient AAV production workflows
Jonathan Zmuda PhD
Jonathan Zmuda PhD
Director, Cell Biology, Thermo Fisher Scientific

Jonathan Zmuda, Ph.D. is a Director of Cell Biology R&D within the Biosciences Division of Thermo Fisher Scientific located in Frederick, MD (USA). Within Cell Biology, Jon leads various teams that focus on developing new technologies for protein expression, viral vector production, transfection and classical cell culture. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park and his undergraduate degree from Dickinson College in Carlisle, PA.

Premkumar Jayaraman PhD
Premkumar Jayaraman PhD
Senior Application Scientist, Cell and Gene Therapy (Asia Pacific and Japan), Thermo Fisher Scientific

Dr. Premkumar Jayaraman currently provides technical consultation for Thermo Fisher Scientific’s cell and gene therapy solutions such as the Gibco Cell Therapy Systems (CTS) brand of products. Prem has over a decade of expertise in synthetic biology utilizing gene-editing technologies, stem cell bioprocessing (pluripotent and adult stem cells), and viral vector production (lentivirus and adeno-associated viruses). In his previous role as a Research Scientist at the Bioprocessing Technology Institute (A*STAR, Singapore), Prem oversaw a variety of cell and gene therapy projects, from media optimization to upstream process development. Prem received his doctoral degree in Biotechnology from Nanyang Technological University (Singapore). He is currently pursuing his Professional MBA at Nanyang Business School.